CA3071405A1 - 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs - Google Patents

1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs Download PDF

Info

Publication number
CA3071405A1
CA3071405A1 CA3071405A CA3071405A CA3071405A1 CA 3071405 A1 CA3071405 A1 CA 3071405A1 CA 3071405 A CA3071405 A CA 3071405A CA 3071405 A CA3071405 A CA 3071405A CA 3071405 A1 CA3071405 A1 CA 3071405A1
Authority
CA
Canada
Prior art keywords
cancer
compound
alkyl
optionally substituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3071405A
Other languages
English (en)
French (fr)
Inventor
Peter Qinhua HUANG
Brant Clayton BOREN
Kevin Duane Bunker
Hui Liu
Sunil Paliwal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recurium IP Holdings LLC
Original Assignee
Recurium IP Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium IP Holdings LLC filed Critical Recurium IP Holdings LLC
Publication of CA3071405A1 publication Critical patent/CA3071405A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3071405A 2017-08-01 2018-07-31 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs Pending CA3071405A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539734P 2017-08-01 2017-08-01
US62/539,734 2017-08-01
PCT/US2018/044580 WO2019028008A1 (en) 2017-08-01 2018-07-31 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES

Publications (1)

Publication Number Publication Date
CA3071405A1 true CA3071405A1 (en) 2019-02-07

Family

ID=65233095

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3071405A Pending CA3071405A1 (en) 2017-08-01 2018-07-31 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs

Country Status (16)

Country Link
US (2) US11124518B2 (enExample)
EP (1) EP3661918B1 (enExample)
JP (1) JP7203816B2 (enExample)
KR (1) KR20200034781A (enExample)
CN (1) CN111094253B (enExample)
AR (1) AR112774A1 (enExample)
AU (1) AU2018312448B2 (enExample)
BR (1) BR112020002104A2 (enExample)
CA (1) CA3071405A1 (enExample)
ES (1) ES2980537T3 (enExample)
IL (1) IL272262A (enExample)
MX (1) MX2020001235A (enExample)
RU (1) RU2020105058A (enExample)
SG (1) SG11202000789WA (enExample)
TW (1) TW201910335A (enExample)
WO (1) WO2019028008A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019074979A1 (en) * 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2019074981A1 (en) 2017-10-09 2019-04-18 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AND USES THEREOF
CA3088997A1 (en) * 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
US11261192B2 (en) * 2018-03-09 2022-03-01 Recurium Ip Holdings, Llc Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones
CN110872296B (zh) * 2018-08-31 2023-05-23 上海弘翊生物科技有限公司 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用
US20220220115A1 (en) * 2019-04-09 2022-07-14 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
EP3952876A4 (en) * 2019-04-09 2023-04-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
WO2020210375A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
CN112142748B (zh) * 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN112142747B (zh) 2019-06-28 2024-03-01 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN112442049A (zh) * 2019-09-03 2021-03-05 微境生物医药科技(上海)有限公司 作为Wee1抑制剂的嘧啶衍生物
MX2022005402A (es) 2019-11-15 2022-07-11 Recurium Ip Holdings Llc Sintesis quiral de un alcohol terciario.
JP7631348B2 (ja) * 2019-12-20 2025-02-18 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 組み合わせ
CA3182270A1 (en) * 2020-05-15 2021-11-18 Recurium Ip Holdings, Llc Mono- and combination therapies
US12522607B2 (en) 2020-06-17 2026-01-13 Wigen Biomedicine Technology (shanghai) Co., Ltd. Substituted pyrazolo[3,4-d]pyrimidines as wee-1 inhibitors
WO2022011391A1 (en) 2020-07-09 2022-01-13 Recurium Ip Holdings, Llc Salts and forms of a wee1 inhibitor
CN114805357B (zh) * 2021-01-21 2023-12-19 四川大学 一种靶向setdb1-ttd的小分子抑制剂及其制药用途
EP4332104A4 (en) * 2021-04-30 2025-04-16 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Fused ring compound as a WEE-1 inhibitor, as well as production process and use thereof
KR20240044409A (ko) * 2021-06-04 2024-04-04 아프레아 테라퓨틱스, 인크. Wee1 키나아제 저해제로서 유용한 피리도피리미딘 유도체
WO2023016417A1 (zh) * 2021-08-11 2023-02-16 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
CN117940430B (zh) * 2021-09-22 2025-10-31 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
WO2023166080A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1846408B1 (en) 2005-01-14 2013-03-20 Janssen Pharmaceutica NV 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
PE20080695A1 (es) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
US8329711B2 (en) * 2007-10-23 2012-12-11 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
US9266895B2 (en) * 2012-09-10 2016-02-23 Principia Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
GB201612092D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
RU2020105058A3 (enExample) 2021-11-17
WO2019028008A1 (en) 2019-02-07
CN111094253A (zh) 2020-05-01
KR20200034781A (ko) 2020-03-31
JP7203816B2 (ja) 2023-01-13
CN111094253B (zh) 2023-08-29
TW201910335A (zh) 2019-03-16
IL272262A (en) 2020-03-31
RU2020105058A (ru) 2021-09-02
AU2018312448B2 (en) 2022-09-15
ES2980537T3 (es) 2024-10-01
BR112020002104A2 (pt) 2020-08-04
US20200157112A1 (en) 2020-05-21
EP3661918A1 (en) 2020-06-10
US11124518B2 (en) 2021-09-21
US20210317124A1 (en) 2021-10-14
EP3661918A4 (en) 2021-05-12
JP2020529993A (ja) 2020-10-15
AR112774A1 (es) 2019-12-11
EP3661918C0 (en) 2024-05-08
AU2018312448A1 (en) 2020-02-13
MX2020001235A (es) 2020-07-20
EP3661918B1 (en) 2024-05-08
SG11202000789WA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
EP3661918B1 (en) 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-one analogs
JP7614255B2 (ja) 置換１，２－ジヒドロ－３Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－３－オン
JP6105578B2 (ja) 複素環式プロテインキナーゼ阻害剤
WO2020210320A1 (en) Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
WO2023049691A1 (en) Cdk7 inhibitors and methods of treating cancer
CA3162963A1 (en) Macrocyclic compounds
RU2847224C2 (ru) Замещенные 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-оны
RU2812726C2 (ru) Замещенные 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-оны
HK40043303B (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
HK40043303A (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones